Loganin exerts neuroprotective effect by inhibiting neuronal pyroptosis in rat with cerebral haemorrhage

Abstract

Intracerebral haemorrhage (ICH) presents significant challenges in clinical management because of the high morbidity and mortality, necessitating novel therapeutic approaches. This study aimed to assess the neuroprotective effects of loganin in a rat ICH model. Sprague–Dawley rats were used, subjected to a collagenase‐induced ICH model, followed by loganin treatment at doses of 2.5, 5 and 10 mg/kg. Neurological functions were evaluated using the modified neurological severity score (mNSS) and a rotarod test. Results indicated a significant improvement in neurological functions in loganin‐treated groups, evident from the mNSS and rotarod tests, suggesting dose‐dependent neuroprotection. Loganin also effectively reduced the blood–brain barrier (BBB) permeability and cerebral oedema. Additionally, it mitigated cellular pyroptosis, as shown by terminal deoxynucleotidyl transferase dUTP nick‐end labelling staining and western blot analysis, which indicated reduced levels of pyroptosis markers in treated rats. Furthermore, loganin's regulatory effects on the adenosine A2A receptor and myosin light chain kinase pathways were observed, potentially underpinning its protective mechanism against ICH. The study concludes that loganin exhibits significant neuroprotective properties in a rat ICH model, highlighting its potential as a novel therapeutic strategy. Despite promising results, the study needs further research to determine loganin's therapeutic potential in human ICH patients. This research paves the way for further exploration into loganin's clinical applications, potentially revolutionizing treatment strategies for patients suffering from intracerebral haemorrhage.

Pyroptosis in Diabetic Peripheral Neuropathy and its Therapeutic Regulation

“… 240 Wang and co-workers have shown that LGN exerts remarkable neuroprotective actions by alleviating neuronal pyroptosis in rats with cerebral hemorrhage. 241 Recently, Kong et al reported that LGN ameliorates diabetic renal injury by obstructing the activation of NLRP3 inflammasome-dependent pyroptosis. 242 Li and co-workers also indicated that LGN treatment attenuated OGD/R-induced cardiomyocyte pyroptosis by alleviating cell membrane damage and inhibiting the pyroptosis-related protein expression level of Cleaved Caspase-1, IL-1β and IL-18.…”